Find out what the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program focusing on extended-release and long-acting opioid analgesic medications is all about, in an interview with Edwin A. Salsitz, MD.

Learn how you can use The ASAM Criteria to determine what kind of care a patient with an addiction needs and help ensure funding for that treatment, in an interview with David Mee-Lee, MD.

Addiction and violence are often linked. Despite this, few studies have looked at whether substance abuse treatment reduces aggressive behavior.

After reading these articles, you should be able to…

Today’s conversation about “smart drugs” is fundamentally different and refers to the use of medications by people without psychiatric disorders who seek a boost or cognitive edge.

Americans guzzled a mind-blowing 3.5 billion energy drinks in 2013, with sales totaling $8.7 billion. But what, exactly, are energy drinks? Do they actually give you energy? And are they safe?

Get insight into the problem of malingering—in other words faking—ADHD symptoms by patients who may want to receive academic accommodations or obtain prescription stimulants, in an interview with researcher Mandi Musso, PhD.

Learn some of the key best practices that can help you work with patients in substance abuse treatment who also have a traumatic brain injury, in an interview with Duane Reynolds, LSW, LADC, associate director of the Vinland National Center in Minnesota.

Find out more about how you can evaluate and treat ADHD symptoms in patients with addiction, in an interview with clinical neuropsychologist Christopher B. Mertz.

Buprenorphine (Suboxone and others) is an effective medication for treating patients with opioid addiction. Research has shown that it works better than standard psychosocial or “abstinence-based” treatments. But is the cost of the drug worth the extra therapeutic benefit?